326-73-8

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-CHLORO-THIOPHEN-2-YL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE is used as an intermediate compound for the development of new pharmaceuticals. Its unique structure and potential reactivity allow for the creation of a variety of compounds with different chemical and biological properties, which can be tailored for specific therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(5-CHLORO-THIOPHEN-2-YL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE serves as a valuable building block. Its electron-withdrawing properties and the presence of a fluorine atom make it a useful component in the synthesis of various complex organic molecules, potentially leading to novel materials and compounds with diverse applications.
Used in Chemical Research:
1-(5-CHLORO-THIOPHEN-2-YL)-4,4,4-TRIFLUORO-BUTANE-1,3-DIONE is also utilized as a subject of study in chemical research. Its unique structure and potential reactivity make it an interesting target for exploring new reaction pathways, understanding molecular interactions, and discovering new properties that could be beneficial in various scientific fields.

Upstream product

• 6310-09-4 2-acetyl-5-chlorothiophene 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 1068105-63-4 N-tert-butyl-3-{1-[4-(5-chlorothiophen-2-yl)-6-trifluoromethylpyrimidin-2-yl]-1H-imidazol-4-yl}benzenesulfonamide 
• 1068105-55-4 3-{1-[4-(5-chlorothiophen-2-yl)-6-trifluoromethylpyrimidin-2-yl]-1H-imidazol-4-yl}benzenesulfonamide 

Relevant academic research and scientific papers

PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS

The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formula (I) are represented by general formula (I) wherein Q, A, B, X, Y, R 1 and R 2 are defined as in the specification.

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib)

A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC- 236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.